Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
I wrote a blog post years ago about my increased risk of both non-melanoma skin cancer as well as melanoma. I wanted to document how the aggressive chemotherapy and radiation I underwent increased my risk of skin cancer.
According to the top study linked and excerpted below, there is an increased risk of skin cancer for the multiple myeloma (MM) patient in years 1-5 following his/her diagnosis of MM. My read of the study is that it is the blood cancer itself that is increasing the MM patient’s skin cancer risk.
My thinking (just a theory mind you…) is that because MM lowers the patient’s immune function, lowers his/her white blood cells, the patient is more susceptible to skin cancer. A common symptom of MM is an increased risk of colds, the flu, and even a proven increased risk of Covid-19.
The point of this post is not to scare newly diagnosed multiple myeloma patients. The point of this post is to:
I understand that managing MM alone is extremely difficult. Both emotionally and physically. Many of the evidence-based therapies shown to reduce skin cancer are the very same evidence-based but non-conventional therapies that have been shown to kill monoclonal proteins aka multiple myeloma.
Consider lifestyle changes such as:
I say “stay out of the sun” because I didn’t at first. I went skiing with my brother the winter after my ASCT. My oncologist hadn’t said anything about my increased risk of skin cancer. My face got fried after the very first day of skiing.
A diagnosis of multiple myeloma is about much more than surgery, chemotherapy and radiation. Yes, conventional oncology is an important piece of the puzzle. But only a piece.
If you have any questions or comments scroll down the page, write a post and I will reply to you ASAP.
“Patients with multiple myeloma (MM) may be more likely to develop melanoma than the general population, according to a poster presented at 2022 American College of Mohs Surgery Annual Meeting. They also may face a higher overall but not melanomas-specific mortality rate, the findings showed…
Factors the researchers examined in this cohort of 177 men and 84 women included: sex, age at MM diagnosis, race, Hispanic origin, household income, urban versus rural geographic location, anatomic location of the tumor(s), Breslow thickness, all-cause mortality, melanoma-specific mortality, and survival duration.
The summary of that examination featured in the poster showed:
1. Melanoma incidence was higher in patients in the following categories:
2. Melanoma patients with MM vs all melanomas demonstrated:
Using this data, the authors concluded that, “Compared with the general population, patients with MM appear to demonstrate a higher incidence of melanoma and overall mortality.”
They also identified some other highlights. “Incidence trends were significant in female patients, White and Black race, non-Hispanic patients, patients with household incomes of $75,000 or more annually, and patients from metropolitan areas,” the authors wrote. Evaluated against all melanoma patients, those with MM were more likely to develop more melanomas on their trunks/extremities and to have thicker melanomas.
“The link between melanoma and chronic lymphocytic leukemia and lymphomas had been previously reported, but little was known about the prevalence and characteristics of melanoma in multiple myeloma,” noted the authors. “Our study sought to better understand the diagnosis of melanoma among patients with multiple myeloma.”
“Importance: Hematopoietic cell transplantation has increased the survival of patients with several types of malignant hematologic disease and hematologic disorders; however, these patients have an increased risk of posttransplant cutaneous malignant neoplasms. Physicians should be aware of associated risk factors to provide appropriate patient screening and long-term care…
Findings: Patients who underwent hematopoietic cell transplantation had an increased risk of:
Factors such as primary disease, chronic graft-vs-host disease, prolonged immunosuppression, radiation exposure, light skin color, sex, and T-cell depletion are risk factors for cutaneous malignant neoplasms.
Conclusions and relevance: Given the increased risk of cutaneous malignant neoplasms in hematopoietic cell transplant recipients, this population should be educated on skin self-examination and pursue regular follow-up with dermatologists.”
“Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. It may be autologous (the patient’s own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin).
It is most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. In these cases, the recipient’s immune system is usually destroyed with radiation or chemotherapy before the transplantation. Infection and graft-versus-host disease are major complications of allogeneic HSCT.…”